Clinical trials: Viremia
HIV Infection
Intermittent vs. Continuous HAART to Treat Chronic HIV Infection
This study will evaluate the effects of intermittent short cycles of HAART (highly active antiretroviral therapy) for treating HIV infection.
- Trial name
- NCT00025909
- Testing
- Leukapheresis
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
HIV in Specific Parts of the Body of Patients Who Are Changing or Starting Potent Anti-HIV Drugs
The purpose of this study is to gain information on how the type and amount of HIV present in certain places in the body and in the blood are affected when potent (powerful) anti-HIV drugs are given.
- Trial name
- NCT00007488
- Where
- 23 sites in United States
- Volunteers
- 164 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Heart Failure
HCV Positive Heart Donors
Study subjects active on the waiting list for a heart transplant at the NYU Langone Transplant Institute who are hepatitis C (HCV) negative will receive a heart transplant from a donor who tests positive for HCV.
- Trial name
- NCT03382847
- Testing
- Transplant with HCV positive donor, followed by surveillance and treatment of viremia
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- NYU Langone Health
Kidney Transplantation, Cytomegalovirus Infections, EBV Infection
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
Opportunistic CMV viremia (primary infection or reactivation) is usually managed by taking prophylactic medication for both adult and pediatric kidney transplant patients.
- Conditions
- Kidney Transplantation, Cytomegalovirus Infections, EBV Infection, Antiviral Prophylaxis
- Trial name
- NCT07294547
- Testing
- Valacyclovir (Valtrex), Valganciclovir (Valcyte)
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
HIV-1-infection
PET Imaging of Radiolabeled Anti-HIV-1 Envelope Monoclonal Antibody (VRC01)
This is a single center exploratory imaging study involving one intravenous microdose of 89Zr-DFO-VRC01 followed by whole-body PET-MR imaging in HIV infected individuals and healthy volunteers.
- Trial name
- NCT03729752
- Testing
- [89]Zr-DFO-VRC-HIVMAB060-00-AB
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Chronic Hepatitis B
The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment
The goal of this observational study is to explore the efficacy and safety of Tenofovir Amibufenamide (TMF) in Entecavir (ETV) treated chronic hepatitis B patients with low-level viraemia.
- Trial name
- POWER (NCT05755776)
- Testing
- TMF
- Where
- 13 sites in China
- Volunteers
- 204 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
BK Viremia, Kidney Transplant Infection
A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients
BEAT-BK will see the effect of immunosuppression reduction/modification with and without IVIG on BKPyV infection, allograft function, allograft loss, acute transplant rejection, immunosuppression load and death in kidney and…
- Conditions
- BK Viremia, Kidney Transplant Infection, Kidney Transplant Failure and Rejection
- Trial name
- BEAT-BK (NCT05325008)
- Testing
- Immunosuppression reduction/modification + intravenous immunoglobulin, Immunosuppression reduction/modification
- Where
- 13 sites in Australia
- Volunteers
- 280 people
- Sponsor
- The University of Queensland
Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
The purpose of this trial is to evaluate a CMV vaccine given to related donor/recipient pairs (donors prior to peripheral blood stem cell donation and CMV-seropositive recipients just before and after transplantation) and…
- Conditions
- Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Hodgkin's Lymphoma
- Trial name
- NCT00285259
- Testing
- VCL-CB01, Phosphate-buffered Saline (PBS)
- Where
- 22 sites in United States
- Volunteers
- 112 people
- Sponsor
- Astellas Pharma Inc
EBV Viremia, CMV Viremia
Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients
The aim of our study is to reduce viral (CMV and EBV) transmission from donor to recipient. The discovery that anti-retroviral therapy to mothers with HIV reduced transmission of the virus to their babies was pivotal to the…
- Trial name
- NCT01329185
- Testing
- Valganciclovir
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Minnesota
CMV Infection, Persistent CMV Viremia
Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to see how well transfusions of T-cells work in treating CMV. Tcells are a type of white blood cell that helps protect the body from infection.
- Trial name
- NCT02136797
- Testing
- CMVpp65 Specific T-cells
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
BK Virus (BKV) Viremia
BK Virus Infection (Viremia) Natural History in Renal Transplant Recipients
The objectives of this study is to establish the natural history of BK virus viremia and other possible opportunistic viral pathogens in renal transplants recipients.
- Trial name
- NCT01782209
- Where
- 6 sites in United States
- Volunteers
- 335 people
- Sponsor
- University of Alabama at Birmingham
BK Viremia
BK Treatment Study
Our hypothesis is that 30 days of oral levofloxacin (FDA approved antibiotic) in patients with persistent viremia (BK virus found in blood) will impair progress to BK virus induced kidney damage by significantly decreasing or…
- Trial name
- NCT01034176
- Testing
- levofloxacin
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- Brigham and Women's Hospital
Adenovirus
Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia
This is a randomized, controlled, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetic (PK), and adenovirus (AdV) antiviral activity of multiple ascending doses of IV brincidofovir (BCV).
- Trial name
- NCT03532035
- Testing
- Brincidofovir, Standard of Care
- Where
- 8 sites in United States, Italy and 1 more
- Sponsor
- Jazz Pharmaceuticals
West Nile Fever
Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
The purpose of this study is to determine whether a single subcutaneous injection of ChimeriVax-WN02 vaccine is well tolerated, safe and induces protective antibodies against West Nile Disease.
- Trial name
- NCT00442169
- Testing
- ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose
- Where
- 5 sites in United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Polyomavirus Infections, BK Viremia
Prevalence of BK Viremia in Simultaneous Liver-Kidney Transplant
The human BK polyomavirus is a significant risk factor for renal transplant dysfunction and allograft loss. The prevalence of BK viremia (BKV) following kidney transplantation is estimated to be 10-20%.
- Conditions
- Polyomavirus Infections, BK Viremia, Liver Transplant Infection, Kidney Transplant Infection
- Trial name
- NCT05224583
- Testing
- Simultaneous Liver-Kidney Transplant
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Methodist Health System
HIV Infection
Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
Background: Antiretroviral therapy (ART) has been able to improve the lifespan of individuals infected with human immunodeficiency virus type 1 (HIV-1), but ART requires continuous treatment that has substantial consequences on…
- Trial name
- NCT01295515
- Testing
- Pegylated Interferon Alpha 2b (PEGINTRON)
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Acute Leukemia, CMV Viremia
The Molecular Mechanism of CMV-driven NKG2C+NK Cell Expansion in Human
This is an observation study to investigate the molecular mechanism of NKG2C+NK cell expansion after HCMV infection
- Conditions
- Acute Leukemia, CMV Viremia, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT04298502
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Allogeneic Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Reactivation
A Randomized Controlled Trial of Prophylactic Rituximab to Reduce Clinically Significant EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
This is a single-center, prospective, randomized, open-label clinical trial with blinded endpoint assessment for patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Reactivation, Clinically Significant EBV DNAemia
- Trial name
- NCT07703657
- Testing
- Rituximab (Arm A), Standard Post-Transplant Supportive Care
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Yang Donglin
Hiv, Transmission Vertical
Enhanced Mentor Mother Strategy for Pregnant and Postpartum Women Living With HIV
Mentor Mothers (MMs) are peer supporters who help pregnant and postpartum women living with HIV (WLHIV) as they receive prevention of mother-to-child transmission of HIV (PMTCT) services in resource-limited settings like Kenya.
- Conditions
- Hiv, Transmission Vertical, Viremia, Adherence, Treatment
- Trial name
- PIE-eMMs (NCT06999928)
- Testing
- Enhanced Mentor Mother Strategy
- Where
- Kenya
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Indiana University
HIV-1-infection
Genotype-Informed Versus Empiric Management of VirEmia
HIV infection can be effectively controlled with antiretroviral therapy (ART). However, children and adolescents living with HIV and receiving ART suffer high rates of treatment failure, predominantly caused by suboptimal…
- Trial name
- GIVE MOVE (NCT04233242)
- Testing
- Clinical management informed by HIV-1 genotypic resistance testing
- Where
- 10 sites in Lesotho, Tanzania
- Volunteers
- 286 people
- Sponsor
- Swiss Tropical & Public Health Institute